Mesenchymal stromal cells encapsulated in licensing hydrogels exert delocalized systemic protection against ulcerative colitis via subcutaneous xenotransplantation

• Published in: European journal of pharmaceutics and biopharmaceutics Vol. 172; pp. 31 - 40
• Main Authors: Gonzalez-Pujana, Ainhoa, Beloqui, Ana, Javier Aguirre, José, Igartua, Manoli, Santos-Vizcaino, Edorta, Maria Hernandez, Rosa
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2022
• Subjects: Hydrogel; Immunomodulation; Inflammatory bowel diseases (IBD); Inflammatory licensing; Mesenchymal stromal cell (MSC); Subcutaneous delivery; Inflammatory licensing; Subcutaneous delivery; Hydrogel; Mesenchymal stromal cell (MSC); Immunomodulation; Inflammatory bowel diseases (IBD)
• ISSN: 0939-6411; 1873-3441
• DOI: 10.1016/j.ejpb.2022.01.007

[Display omitted] The ability of mesenchymal stromal cells (MSCs) to release a plethora of immunomodulatory factors makes them valuable candidates to overcome inflammatory bowel diseases (IBD). However, this cell therapy approach is still limited by major issues derived from nude MSC-administration, including a rapid loss of their immunomodulatory phenotype that impairs factor secretion, low persistence and impossibility to retrieve the cells in case of adverse effects. Here, we designed a licensing hydrogel system to address these limitations and thus, obtain a continuous delivery of bioactive factors. IFNγ-loaded heparin-coated beads were included in injectable in situ crosslinking alginate hydrogels, providing a 3D microenvironment that ensured continuous inflammatory licensing, cell persistence and implant retrievability. Licensing-hydrogel encapsulated human MSCs (hMSCs) were subcutaneously xenotransplanted in an acute mouse model of ulcerative colitis. Results showed that encapsulated hMSCs exerted a delocalized systemic protection, not presenting significant differences to healthy mice in the disease activity index, colon weight/length ratio and histological score. At day 7, cells were easily retrieved and ex vivo assays showed fully viable hMSCs that retained an immunomodulatory phenotype, as they continued secreting factors including PGE2 and Gal-9. Our data demonstrate the capacity of licensing hydrogel-encapsulated hMSCs to limit the in vivo progression of IBD.